New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
07:45 EDTVIVOMeridian Bioscience price target raised to $24 from $22 at RW Baird
Baird raised its price target on Meridian Bioscience following meeting with management. The firm believes investors sentiment is low but feels comfortable with guidance and management strategy for growth. Shares are Outperform rated.
News For VIVO From The Last 14 Days
Check below for free stories on VIVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
07:26 EDTVIVOAmerican Association for Clinical Chemistry to hold annual meeting
Subscribe for More Information
July 24, 2014
08:17 EDTVIVOMeridian Bioscience reaffirms FY14 EPS view 85c-90c, consensus 88c
Reaffirms FY14 revenue view $190M-$195M, consensus $192.97M. Says financial condition is "sound."
08:16 EDTVIVOMeridian Bioscience reports Q3 EPS 21c, consensus 23c
Subscribe for More Information
July 22, 2014
07:08 EDTVIVOLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use